Alembic Improdiet Nutritional Supplement Syrup for Dogs & Cats | Liver Health, Appetite Stimulant & Digestive Support | 200ml

FOR VETERINARY USE — Administer as directed by a licensed veterinarian. Use under veterinary supervision. Shake well before use. Keep out of reach of children. Store in a cool, dry place away from direct sunlight.

Alembic Improdiet Nutritional Supplement Syrup for Dogs & Cats | Liver Health, Appetite Stimulant & Digestive Support | 200ml

Alembic Improdiet is a veterinary nutritional supplement syrup for dogs and cats, formulated as a multi-action hepatoprotective, appetite-stimulating, and digestive-support preparation. Improdiet addresses three overlapping clinical problems commonly seen together in sick, convalescent, and nutritionally compromised pets: hepatic dysfunction (reduced hepatic detoxification and biotransformation capacity), anorexia or hyporexia (reduced voluntary food intake), and impaired digestion and nutrient absorption (reduced digestive enzyme activity and GI motility). By supporting all three systems simultaneously, Improdiet helps restore positive energy balance, improve body condition score, and accelerate clinical recovery. Use as directed by a licensed veterinarian.

Key Active Components & Mechanism of Action

• Hepatoprotective agents — Silymarin (Milk Thistle — Silybum marianum seed extract) and/or liver extract (confirm from Alembic Improdiet label): Silymarin is a polyphenolic flavonolignan complex (principal components: Silybin A and B — ~50–60% of Silymarin; Silychristin, Silydianin, and Isosilybin — remaining flavonolignans) extracted from Silybum marianum (Milk Thistle) seeds; hepatoprotective mechanisms: (1) Antioxidant/free radical scavenging — Silybin is a potent scavenger of reactive oxygen species (ROS: superoxide anion O2•−, hydroxyl radical HO•, hydrogen peroxide H2O2, and peroxyl radical ROO•) via direct electron donation from the catechol B-ring of the flavonolignan structure; Silybin also upregulates endogenous antioxidant enzymes: superoxide dismutase (SOD — converts O2•− → H2O2), catalase (converts H2O2 → H2O + O2), and glutathione peroxidase (GPx — reduces H2O2 and lipid hydroperoxides using GSH as co-substrate); in hepatocytes, oxidative stress from lipid peroxidation of polyunsaturated fatty acids (PUFA) in hepatocyte plasma membranes (generating 4-hydroxynonenal — 4-HNE and malondialdehyde — MDA as electrophilic lipid peroxidation end-products) is a primary mechanism of hepatocellular injury in hepatotoxin exposure, drug-induced liver injury (DILI), inflammatory liver disease, and reactive oxygen species-mediated hepatocyte apoptosis/necrosis; Silymarin interrupts the lipid peroxidation chain reaction by scavenging propagating peroxyl radicals; (2) Hepatocyte membrane stabilisation — Silybin binds competitively to the hepatic cell membrane transport system used by hepatotoxins (e.g. phalloidin from Amanita phalloides — death cap mushroom; aflatoxins; carbon tetrachloride) to enter hepatocytes, reducing hepatotoxin uptake; Silybin also inhibits lipopolysaccharide (LPS)-induced Kupffer cell activation and TNF-α secretion, reducing inflammatory liver injury; (3) Hepatic regeneration promotion — Silybin activates RNA polymerase I in non-neoplastic hepatocytes (hepatocyte-specific stimulation — not demonstrated in hepatocellular carcinoma cells) → increased ribosomal RNA (rRNA) synthesis → enhanced hepatocyte protein synthesis capacity → accelerated hepatocyte regeneration and restoration of hepatic parenchymal mass after hepatocellular injury; (4) Anti-fibrotic action — Silybin inhibits TGF-β-mediated activation of hepatic stellate cells (HSCs — the primary collagen-producing cells responsible for hepatic fibrosis/cirrhosis); inhibits TIMP-1 (tissue inhibitor of metalloproteinase-1), promoting MMP-mediated collagen remodelling and degradation of excess extracellular matrix in fibrotic liver
• Appetite stimulant — Cyproheptadine Hydrochloride (H1 antihistamine / 5-HT2 serotonin antagonist) and/or B-vitamin complex (confirm from label): Cyproheptadine is a first-generation piperidine-class antihistamine with potent additional 5-HT2A and 5-HT2C serotonin receptor antagonist activity; appetite stimulation mechanism: serotonin (5-hydroxytryptamine — 5-HT) acts as an anorexigenic (appetite-suppressing) neurotransmitter via 5-HT2C receptors on pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus; 5-HT2C agonism on POMC neurons stimulates release of α-MSH (alpha-melanocyte-stimulating hormone) → activation of melanocortin-4 receptor (MC4R) in the paraventricular nucleus (PVN) → anorexigenic signalling cascade suppressing food intake; Cyproheptadine blocks 5-HT2C receptors on POMC neurons → reduces α-MSH release → reduces MC4R activation → reduced anorexigenic tone → relative disinhibition of orexigenic pathways (NPY/AgRP neuropeptide Y/agouti-related peptide neurons in the arcuate nucleus) → increased appetite and food intake; additionally, Cyproheptadine’s H1 antihistamine activity may contribute to appetite stimulation via histamine H1 blockade in the hypothalamic ventromedial nucleus (VMN), a satiety centre where histamine exerts anorexigenic effects via H1 receptors; B-vitamin complex (B1 Thiamine, B2 Riboflavin, B3 Niacin, B5 Pantothenic acid, B6 Pyridoxine, B12 Cyanocobalamin, Folic acid): essential coenzymes for intermediary metabolism — Thiamine (as Thiamine Pyrophosphate — TPP) is the cofactor for pyruvate dehydrogenase (PDH — pyruvate → Acetyl-CoA), α-ketoglutarate dehydrogenase (α-KGD — TCA cycle), and transketolase (pentose phosphate pathway); B-vitamin deficiencies are common in anorectic, chronically ill, and post-surgical pets due to inadequate dietary intake and increased metabolic demand; B-vitamin supplementation restores cofactor availability for energy-generating metabolic pathways (glycolysis, TCA cycle, fatty acid β-oxidation, oxidative phosphorylation), directly improving energy status and supporting recovery
• Digestive enzymes (confirm from Alembic Improdiet label): Digestive enzyme supplementation addresses exocrine pancreatic insufficiency (EPI), reduced gastric acid secretion (hypochlorhydria — common in critically ill pets on proton pump inhibitors or H2 blockers), and generalised maldigestion/malabsorption; key enzymes potentially included: Protease (endopeptidases and exopeptidases — protein hydrolysis → amino acids and peptides for intestinal absorption), Lipase (triglyceride hydrolysis → fatty acids + glycerol + monoglycerides — requires bile salt emulsification for micellar solubilisation before absorption by enterocytes via fatty acid translocase/CD36 and FATP4), Amylase (α-1,4-glucosidic bond hydrolysis in starches → maltose, maltotriose, and α-limit dextrins → further hydrolysed by brush border maltase-glucoamylase and sucrase-isomaltase → glucose for SGLT1-mediated intestinal absorption)

Indications

• Anorexia and hyporexia — reduced voluntary food intake due to illness, hospitalisation, stress, chemotherapy, chronic disease, or post-operative recovery
• Hepatic support — adjunctive hepatoprotection in dogs and cats with hepatitis, hepatic lipidosis (fatty liver — particularly common in cats), drug-induced liver injury (DILI), or chronic liver disease
• Malnutrition, cachexia, and poor body condition score (BCS) — nutritional rehabilitation in underweight, debilitated, or chronically ill pets
• Digestive enzyme deficiency — adjunctive support in maldigestion/malabsorption states
• Post-illness and post-surgical convalescence — nutritional support to restore positive energy balance and accelerate recovery
• Nutritional supplementation during periods of high physiological demand — growth, pregnancy, lactation, heavy work or athletic performance

Dosage & Administration

• Shake well before each use
• Administer orally by syringe directly into the mouth or mix into food
• Dose based on body weight, species, and indication as directed by a veterinarian
• Duration of supplementation as directed by veterinarian — for appetite stimulation, response typically seen within 24–48 hours of initiating Cyproheptadine-containing preparations

Safety Information

• For veterinary use — use under veterinary supervision
• Cyproheptadine (if present) may cause mild sedation in some animals due to its H1 antihistamine activity — CNS depression is less pronounced than with classic 1st-generation antihistamines but may be observed
• Do not use concurrently with MAO inhibitors (MAOIs) — risk of serotonin syndrome from 5-HT2 antagonism interaction
• Safety in pregnant and lactating animals has not been fully established — confirm with veterinarian
• Store in a cool, dry place away from direct sunlight; shake well before use; keep tightly capped after use; use within the shelf-life stated on the label